All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Nigel Russell, Guy's and St Thomas' NHS Foundation Trust, London, UK. We asked: How should gemtuzumab ozogamicin be applied in AML?
Here, Nigel Russell discusses the treatment of elderly patients with AML with the CD33-targeted antibody–drug conjugate, gemtuzumab ozogamicin, as part of the AML18 trial. The overall survival and response rates demonstrated by patients, who were randomized to receive either a single dose or a fractionated dosing schedule of gemtuzumab ozogamicin, are outlined.
AML18 trial: How should gemtuzumab ozogamicin be applied in AML?
What are the updates from the NCRI AML18 and AML19 clinical trials?
During the 4th NCRI AML Academy Meeting, the AML Hub was pleased to speak to Nigel Russell, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What are the updates from...
AML Hub Satellite Symposium: How does MRD impact outcome of stem cell transplantation in AML, now and in the future?
At the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub will hold a satellite...
Subscribe to get the best content related to AML delivered to your inbox